TrialCancer2009

Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.

Nitin Jain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.